KR20070047807A - 이소인돌린 화합물 및 그의 사용 방법 - Google Patents

이소인돌린 화합물 및 그의 사용 방법 Download PDF

Info

Publication number
KR20070047807A
KR20070047807A KR1020077004729A KR20077004729A KR20070047807A KR 20070047807 A KR20070047807 A KR 20070047807A KR 1020077004729 A KR1020077004729 A KR 1020077004729A KR 20077004729 A KR20077004729 A KR 20077004729A KR 20070047807 A KR20070047807 A KR 20070047807A
Authority
KR
South Korea
Prior art keywords
disease
inhibitors
cancer
compound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077004729A
Other languages
English (en)
Korean (ko)
Inventor
조지 더블유. 멀러
혼-와 만
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20070047807A publication Critical patent/KR20070047807A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077004729A 2004-07-28 2005-07-27 이소인돌린 화합물 및 그의 사용 방법 Ceased KR20070047807A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/900,332 2004-07-28
US10/900,332 US7405237B2 (en) 2004-07-28 2004-07-28 Isoindoline compounds and methods of their use

Publications (1)

Publication Number Publication Date
KR20070047807A true KR20070047807A (ko) 2007-05-07

Family

ID=35733185

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004729A Ceased KR20070047807A (ko) 2004-07-28 2005-07-27 이소인돌린 화합물 및 그의 사용 방법

Country Status (13)

Country Link
US (3) US7405237B2 (https=)
EP (1) EP1781610A2 (https=)
JP (1) JP2008508298A (https=)
KR (1) KR20070047807A (https=)
CN (1) CN101031545A (https=)
AU (1) AU2005269367B2 (https=)
BR (1) BRPI0513836A (https=)
CA (1) CA2574966A1 (https=)
IL (1) IL180978A0 (https=)
MX (1) MX2007000842A (https=)
NZ (1) NZ553029A (https=)
WO (1) WO2006015060A2 (https=)
ZA (1) ZA200701660B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441096B1 (ko) * 2012-11-27 2014-09-25 가톨릭대학교 산학협력단 제피티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
WO2020036386A1 (ko) * 2018-08-16 2020-02-20 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510606A (ja) * 2002-10-15 2006-03-30 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
NZ540384A (en) * 2002-11-06 2008-06-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
HRP20130102T1 (hr) * 2005-06-30 2013-03-31 Celgene Corporation Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
TW200806625A (en) * 2006-05-26 2008-02-01 Astrazeneca Ab Therapeutic compounds
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
PE20120580A1 (es) 2009-02-10 2012-05-23 Celgene Corp Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
JP5918694B2 (ja) 2009-05-12 2016-05-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ
CN101580501B (zh) * 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
US20120184746A1 (en) * 2009-09-03 2012-07-19 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
CN101747255B (zh) * 2009-12-22 2011-11-23 上海大学 含烯炔结构的异吲哚酮类化合物及其合成方法
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20110318741A1 (en) 2010-06-15 2011-12-29 Schafer Peter H Biomarkers for the treatment of psoriasis
CN102603610B (zh) * 2012-02-21 2014-07-09 四川大学 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途
CN104045594B (zh) * 2012-02-21 2016-08-17 四川大学 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途
CN105358177B (zh) 2013-04-17 2018-11-23 西格诺药品有限公司 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
CN104721820A (zh) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 双特异性单克隆抗体在治疗葡萄膜炎中的用途
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
CR20170005A (es) * 2014-07-08 2017-05-08 Viiv Healthcare Uk Ltd Derivados de insoindolina
EP3324962A4 (en) 2015-07-23 2018-12-19 Temple University Of The Commonwealth System Of Higher Education Novel aminothiazole compounds and methods using same
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
EP3571196B1 (en) * 2017-01-19 2023-01-04 Temple University Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
EP3672939A1 (en) 2017-08-21 2020-07-01 Celgene Corporation Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
WO2021134045A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
CN114644586A (zh) * 2022-04-12 2022-06-21 江苏豪森药业集团有限公司 一种来那度胺有关物质的制备方法
WO2025118133A1 (zh) * 2023-12-05 2025-06-12 浙江普洛家园药业有限公司 一种(s)-来那度胺-5-位衍生物及其合成方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295295A1 (en) 1997-07-31 1999-02-11 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
KR100672892B1 (ko) * 1999-03-18 2007-01-23 셀진 코오퍼레이션 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
WO2003014315A2 (en) 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441096B1 (ko) * 2012-11-27 2014-09-25 가톨릭대학교 산학협력단 제피티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
WO2020036386A1 (ko) * 2018-08-16 2020-02-20 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR20200020607A (ko) * 2018-08-16 2020-02-26 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN112839937A (zh) * 2018-08-16 2021-05-25 韩国化学研究院 异吲哚啉-1-酮衍生物、其制备方法、和包含其作为有效组分的用于预防或治疗癌症的药物组合物
CN112839937B (zh) * 2018-08-16 2023-08-22 韩国化学研究院 异吲哚啉-1-酮衍生物、其制备方法及其用途
US11976059B2 (en) 2018-08-16 2024-05-07 Korea Research Institute Of Chemical Technology Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer

Also Published As

Publication number Publication date
MX2007000842A (es) 2007-04-17
CN101031545A (zh) 2007-09-05
IL180978A0 (en) 2007-07-04
US20090291991A1 (en) 2009-11-26
AU2005269367B2 (en) 2011-12-01
US20080145336A1 (en) 2008-06-19
US7816393B2 (en) 2010-10-19
US20060025457A1 (en) 2006-02-02
AU2005269367A1 (en) 2006-02-09
JP2008508298A (ja) 2008-03-21
WO2006015060A3 (en) 2006-07-20
WO2006015060A2 (en) 2006-02-09
BRPI0513836A (pt) 2008-05-20
US7405237B2 (en) 2008-07-29
CA2574966A1 (en) 2006-02-09
ZA200701660B (en) 2008-09-25
US7569597B2 (en) 2009-08-04
NZ553029A (en) 2010-12-24
EP1781610A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
KR20070047807A (ko) 이소인돌린 화합물 및 그의 사용 방법
KR101131651B1 (ko) 암 및 기타 질환의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 이를 사용하는 조성물
RU2348407C2 (ru) Способы и композиции с использованием иммуномодулирующих соединений для лечения и поддержания состояния при раке и других заболеваниях
KR100822149B1 (ko) 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
US20070254942A1 (en) 7-amido-isoindolyl compounds and methods of its use
KR100923173B1 (ko) 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
JP2010013482A (ja) 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いた方法および組成物
KR20060124607A (ko) 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
CN1984651A (zh) 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
KR20070011564A (ko) 암 및 그 밖의 질환의 치료 및 관리를 위해 선택적사이토킨 억제성 약물을 사용하는 방법 및 조성물
HK1107987A (en) Isoindoline compounds and methods of their use
HK1104969A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100727

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120531

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I